Posted On: 12/06/2014 9:33:09 PM
Post# of 63824
$CYDY breakout staging
$1.20
Website
Shares Outstanding: 55.75M
Float: 48.44M
% Held by Insiders: 15.70%
10-Q 10/10/14
Summary
Recent Trades
80% Buy
Headlines
Monday, November 24, 2014
CytoDyn Information Now Available Through S&P Capital IQ Corporation Records ProgramGlobeNewswire
Thursday, November 20, 2014
CYTODYN INC Files SEC form 8-K, Unregistered Sale of Equity SecuritiesEDGAR Online
Friday, October 17, 2014
CYTODYN INC FinancialsEDGAR Online Financials
Monday, October 13, 2014
CytoDyn Announces 100% Success With PRO 140 in Four-Week Monotherapy Clinical TrialGlobeNewswire
Friday, October 10, 2014
CytoDyn Announces Investment Community Call to Discuss Results From Its Treatment Substitution Clinical Trial in Patients With HIVGlobeNewswire
CYTODYN INC Files SEC form 10-Q, Quarterly ReportEDGAR Online
Wednesday, October 1, 2014
CYTODYN INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance SheetEDGAR Online
CytoDyn Appoints Carl Dockery to Board of DirectorsGlobeNewswire
Monday, August 25, 2014
CYTODYN INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other EventsEDGAR Online
Thursday, July 10, 2014
CYTODYN INC Files SEC form 10-K, Annual ReportEDGAR Online
Thursday, May 15, 2014
CytoDyn to host conference callat theflyonthewall.com
Friday, April 11, 2014
CYTODYN INC Files SEC form 10-Q, Quarterly ReportEDGAR Online
Wednesday, March 19, 2014
CytoDyn Announces Investor Call to Provide Update on Clinical Development StrategyBusiness Wire
Tuesday, February 18, 2014
CytoDyn Submits Protocol to FDA for Phase 2b Clinical Study of PRO 140 for Treatment Substitution in Patients with HIVBusiness Wire
Thursday, February 13, 2014
CYTODYN INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibitsEDGAR Online
CytoDyn Appoints Denis R. Burger, Ph.D. to Board of DirectorsBusiness Wire
Wednesday, February 5, 2014
CytoDyn to Present at 16th Annual BIO CEO & Investor Conference on Monday, February 10, 2014 at 10:00 AM EasternBusiness Wire
Tuesday, January 28, 2014
CytoDyn Signs Agreement with Amarex Clinical Research LLC to Prepare Two Phase 2b Clinical Trial Protocols to Explore Two Additional Therapeutic Indications for PRO 140Business Wire
Friday, January 24, 2014
CYTODYN INC Files SEC form 8-K, Entry into a Material Definitive AgreementEDGAR Online
Monday, January 13, 2014
CYTODYN INC Files SEC form 10-Q, Quarterly ReportEDGAR Online
$1.20
Website
Shares Outstanding: 55.75M
Float: 48.44M
% Held by Insiders: 15.70%
10-Q 10/10/14
Summary
Recent Trades
80% Buy
Headlines
Monday, November 24, 2014
CytoDyn Information Now Available Through S&P Capital IQ Corporation Records ProgramGlobeNewswire
Thursday, November 20, 2014
CYTODYN INC Files SEC form 8-K, Unregistered Sale of Equity SecuritiesEDGAR Online
Friday, October 17, 2014
CYTODYN INC FinancialsEDGAR Online Financials
Monday, October 13, 2014
CytoDyn Announces 100% Success With PRO 140 in Four-Week Monotherapy Clinical TrialGlobeNewswire
Friday, October 10, 2014
CytoDyn Announces Investment Community Call to Discuss Results From Its Treatment Substitution Clinical Trial in Patients With HIVGlobeNewswire
CYTODYN INC Files SEC form 10-Q, Quarterly ReportEDGAR Online
Wednesday, October 1, 2014
CYTODYN INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance SheetEDGAR Online
CytoDyn Appoints Carl Dockery to Board of DirectorsGlobeNewswire
Monday, August 25, 2014
CYTODYN INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other EventsEDGAR Online
Thursday, July 10, 2014
CYTODYN INC Files SEC form 10-K, Annual ReportEDGAR Online
Thursday, May 15, 2014
CytoDyn to host conference callat theflyonthewall.com
Friday, April 11, 2014
CYTODYN INC Files SEC form 10-Q, Quarterly ReportEDGAR Online
Wednesday, March 19, 2014
CytoDyn Announces Investor Call to Provide Update on Clinical Development StrategyBusiness Wire
Tuesday, February 18, 2014
CytoDyn Submits Protocol to FDA for Phase 2b Clinical Study of PRO 140 for Treatment Substitution in Patients with HIVBusiness Wire
Thursday, February 13, 2014
CYTODYN INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibitsEDGAR Online
CytoDyn Appoints Denis R. Burger, Ph.D. to Board of DirectorsBusiness Wire
Wednesday, February 5, 2014
CytoDyn to Present at 16th Annual BIO CEO & Investor Conference on Monday, February 10, 2014 at 10:00 AM EasternBusiness Wire
Tuesday, January 28, 2014
CytoDyn Signs Agreement with Amarex Clinical Research LLC to Prepare Two Phase 2b Clinical Trial Protocols to Explore Two Additional Therapeutic Indications for PRO 140Business Wire
Friday, January 24, 2014
CYTODYN INC Files SEC form 8-K, Entry into a Material Definitive AgreementEDGAR Online
Monday, January 13, 2014
CYTODYN INC Files SEC form 10-Q, Quarterly ReportEDGAR Online
(0)
(0)
